Opus genetics, inc.IRD.US Overview
IRD Overall Performance
IRD AI Analysis & Strategy
IRD Recent Performance
0.56%
Opus genetics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
IRD PowerScanner
IRD Key Information
IRD Valuation Metrics
IRD Earnings Table
IRD Profile
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.